Mutation profile of patients who relapsed on gilteritinib therapy. (A) New mutations at relapse. (B) New Ras/MAPK gene mutations at relapse. (C) New FLT3 mutations at relapse. Analyses were restricted to patients who had blood or bone marrow samples available at both baseline and at relapse. ^†Some patients had mutations in more than 1 Ras/MAPK pathway gene. ^‡One patient acquired a FLT3 F691L gatekeeper mutation as well as a JMD point mutation at relapse.